HerAnova Lifesciences, 2 Burlington Woods Drive Suite 100, Burlington, MA (2026)

03/12/2026

HerAnova will be exhibiting at the PCRS 2026 Annual Meeting in Rancho Mirage, California, March 18–22.

We look forward to connecting with reproductive medicine clinicians and leaders who are advancing thoughtful, evidence-based fertility care.

Visit us at Booth #604 to learn more about HerResolve™, our blood-based test designed to detect and support earlier, biology-informed clinical decision-making within fertility practice.

If you’re attending the PCRS 2026 Annual Meeting, we hope you’ll stop by the booth to meet our team and explore how molecular insight can help inform fertility evaluation and care planning.

Read the full announcement here: HerAnova.com/news-and-events

03/11/2026

As we continue recognizing 🎗, we are highlighting how earlier, more informed detection is shaping real-time decision-making in fertility care.

Across leading fertility practices, physicians are incorporating HerResolve™, our non-invasive blood test designed to detect , to help guide personalized treatment planning when timing and clarity matter most.

As Carrie Wambach, MD, board-certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility at Reproductive Partners Medical Group, shares:

“In fertility care, timing matters. HerResolve™ helps us personalize fertility plans and move to the most effective treatment in a timely manner. That clarity is especially valuable when counseling patients who are already navigating an emotional and time-sensitive fertility journey, providing added confidence at critical decision points.”

Fertility care is both scientific and deeply personal. By delivering meaningful diagnostic insight through a simple blood draw, HerResolve helps reduce uncertainty and supports personalized, biology-informed conversations between physician and patient.

During Endometriosis Awareness Month and beyond, HerAnova remains committed to advancing evidence-based tools that elevate care and bring greater clarity to women’s health.

03/09/2026

A significant milestone for women’s health and research 🎗

HerAnova Lifesciences has published the peer-reviewed clinical validation study of HerResolve™, our non-invasive blood-based assay for detecting endometriosis, in the Journal of Minimally Invasive Gynecology (JMIG) — the official journal of AAGL.

"Endometriosis has long been one of the most underdiagnosed and undertreated conditions in women's health," said Farideh Bischoff, PhD, Chief Medical Officer of HerAnova Lifesciences and corresponding author of the study. "Publication in JMIG represents a meaningful milestone in our mission to bring a reliable, accessible diagnostic tool to the clinicians and patients who need it most. HerResolve™ was designed to work alongside existing imaging and clinical evaluation, filling a critical gap in non-invasive disease detection."

“This publication marks an important step forward for women living with endometriosis who have waited far too long for answers,” said Penny Wan, Chairwoman of HerAnova Lifesciences. “The validation of HerResolve™ in JMIG reinforces the scientific foundation behind our approach and strengthens our commitment to transforming how endometriosis is detected.”

Read the full announcement: HerAnova.com/news-and-events

03/08/2026

International Women’s Day ♀️ is a time to recognize the strength, resilience, and voices of women everywhere—and to continue pushing for progress in women’s health.

This March, during 🎗️💛 , we join the global community in raising awareness for endometriosis, a condition affecting millions of women worldwide.

At HerAnova, we believe women deserve clearer answers and better tools for detection. Through innovations like HerResolve™, our blood-based test designed to help detect endometriosis, we are working to bring greater visibility, understanding, and diagnostic clarity to this complex disease.

Today, we stand with women, clinicians, researchers, and advocates around the world who are working to move women’s health forward.

her health, our mission.

03/05/2026

March is 🎗️ — a time to bring greater visibility to the diagnostic challenges women continue to face and the importance of clearer, earlier answers.

At HerAnova, we are honored to see reproductive endocrinologists and fertility specialists incorporating HerResolve™, our non-invasive blood test designed to detect endometriosis, into clinical practice to help inform care at critical decision points in a woman’s fertility journey.

As Mary Peavey, MD, MSCR, a fertility specialist with Atlantic Fertility , shares:
“Endometriosis affects one in ten women of reproductive age. That’s why incorporating the HerResolve blood test to detect endometriosis has been so meaningful in my practice. It gives both physician and patient the confidence to move forward knowing the plan is informed, intentional, and aligned with her biology.
For years, the field has needed clearer answers in these pivotal moments. HerResolve brings that clarity when it matters most.”

As a non-invasive blood test designed to detect endometriosis, HerResolve offers physicians meaningful diagnostic insight through a simple blood draw, helping reduce uncertainty while supporting patients with greater comfort and confidence.

This Endometriosis Awareness Month, we remain committed to advancing evidence-based detection and elevating the standard of women’s health.

03/02/2026

At HerAnova, we are committed not only to advancing care, but also to expanding access. We’ve updated the Products page on our website to include a map highlighting U.S. IVF centers currently offering HerResolve™ to IVF patients.

HerResolve™ is our blood-based test designed to detect endometriosis in symptomatic women, helping bring molecular insight into fertility care and supporting more informed clinical conversations.

We invite you to explore the updated page, see where HerResolve™ is available, and contact us about availability in your area.

Visit HerAnova.com/products to learn more.

02/23/2026

HerAnova Lifesciences is proud to announce the commercialization of HerResolve™ — the first and only non-invasive blood test to detect , now in clinical use at leading IVF and reproductive medicine centers across the United States.

Current locations include Reproductive Partners Medical Group in Southern California, CNY Fertility centers nationwide, and Atlantic Fertility — with a growing network of partners continuing to expand.

For 1 in 10 women of reproductive age, endometriosis is a daily reality. For too many of them, getting a diagnosis takes 7 to 10 years — years of pain, uncertainty, and unanswered questions. HerResolve™ was developed to change that and this commercialization milestone, timed ahead of this March, is only the beginning.

View the full press release here: https://bit.ly/4rbQTfr
To find your nearest location, visit www.HerAnova.com/products

02/20/2026

is not just a pelvic condition. Research continues to show that it is linked to broader inflammatory and metabolic processes in the body.

A recent 2026 review in the International Journal of Molecular Sciences explores how advanced glycation end products, or AGEs, may contribute to sustained inflammation and tissue changes in endometriosis. These compounds form naturally in the body and are influenced by metabolic health and diet. When AGEs interact with their receptor, RAGE, they may help keep inflammatory pathways active in established lesions.

Read the full study here: https://bit.ly/4tE7Dhw

As our understanding of these systemic drivers grows, the importance of earlier, biology-informed evaluation becomes even clearer.

That's where HerResolve™ comes in.

HerResolve™ is our blood-based test designed to detect endometriosis. By supporting earlier identification when symptoms raise concern, HerResolve™ helps bring molecular insight into clinical decision-making and supports clearer, more informed conversations between patients and providers.

Advancing research is shaping the future of endometriosis care. Earlier detection is part of that progress.

02/18/2026

Dr. Farideh Bischoff, Chief Medical Officer and Head of Diagnostics at HerAnova, will participate in a featured panel discussion at the upcoming HERS: Health Executive & Research Summit, taking place March 23–24 in San Diego, CA.

She will join the panel titled “Redefining Women’s Health: Diagnostics, Data, and Disruption” on Tuesday, March 24 at 2:45 PM, where industry leaders will explore how clinically validated diagnostics, advanced data strategies, and bold innovation models are reshaping the future of women’s healthcare.

For full program details and registration information, visit www.hersusa.com/venture. Attendees may use code SPK150 for a $150 discount, with advance registration rates available through February 20.

We look forward to engaging with peers across biotech, clinical care, and investment who are driving meaningful progress in women’s health.

02/13/2026

HerAnova will be presenting and exhibiting at the American & Global College of Endometriosis Specialists (AGCES) Annual Meeting, March 19–21, 2026 at the Fontainebleau Las Vegas.

We invite attendees to visit us at Booth #4 to learn more about HerResolve™, our non-invasive, blood-based test designed to detect endometriosis and support earlier, more informed clinical decision-making in women’s health.

We are also proud to share that our Chief Medical Officer, Farideh Bischoff, PhD, will present a scientific poster entitled 'Laboratory Validation of Noninvasive Blood Test to Predict Presence or Absence of Endometriosis Histology vs Visual Laparoscopy as Ground Truth', highlighting HerAnova’s ongoing research and commitment to evidence-driven innovation.

If you plan to attend, we encourage you to connect with us in advance to schedule time to meet. We look forward to engaging with colleagues and advancing the conversation around endometriosis detection and women’s health.

Learn more here: https://www.agcesmeeting.org/

02/11/2026

presents with a wide range of symptoms, and not every patient will experience them all. This whole-body disease can go undiagnosed for years, often becoming more apparent only once symptoms grow severe.

The The Endometriosis Foundation of America emphasizes the importance of consulting an OB/GYN or endometriosis specialist, advocating for second opinions when necessary, and seeking comprehensive evaluation when symptoms persist.

At HerAnova, we are committed to advancing women’s health through earlier and more precise detection. HerResolve™, our non-invasive blood-based test designed to detect endometriosis, reflects our focus on improving the diagnostic pathway and supporting more informed clinical decision-making.

We encourage you to review the full article from EndoFound to better understand the breadth of symptoms and when to seek care:

https://www.endofound.org/endometriosis-symptoms

02/03/2026

We’re pleased to share that HerAnova’s Chief Medical Officer and Head of Diagnostics, Dr. Farideh Bischoff, has been selected to join a panel discussion alongside fellow women’s health diagnostics leaders from Roche and Hologic at the HERS: Health Executive & Research Summit), taking place March 23–24 in San Diego, CA.

The summit brings together leaders across women’s health, research, and innovation to explore emerging science and real-world impact. The organizers are offering discounted registration for attendees, with details available at www.hersusa.com/venture (Code: SPK150).

We look forward to contributing to the conversation on advancing innovation and leadership in women’s health! Connect with us if you'll be there!

HerAnova Lifesciences

03/12/2026

03/11/2026

03/09/2026

03/08/2026

03/05/2026

03/02/2026

02/23/2026

02/20/2026

02/18/2026

02/13/2026

02/11/2026

02/03/2026

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category